Compare Ginkgo Bioworks Holdings Inc (DNA) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs LYFT Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while LYFT Inc trades at $16.16 (market cap $6.11B). The key difference: LYFT Inc is far larger — about 8× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and LYFT Inc for 47 Days on average.
| DNA | LYFT | |
|---|---|---|
Market Cap | $763.64M | $6.11B |
Volume | 3,204,177 | 13,504,560 |
Sector | Health | Technology |
52-Week High | $15.83 | $24.57 |
52-Week Low | $5.48 | $12.65 |
Typical Hold Time | 7 Days | 47 Days |
Enterprise Value | $865.59M | $5.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
Lyft trades at $15.60, down 1.02% on the day, with a bullish technical outlook supported by moving averages despite recent earnings misses. The company shows strong profitability with 45.52% gross margins and 42.32% net income margin, while recent developments include European expansion and a $272.5M legal settlement. Cash flow has improved significantly, with operating cash flow reaching $1.17B in 2025.
Lyft presents a mixed investment case with attractive valuation metrics (P/E 2.35, P/S 0.96) but faces execution risks from recent earnings misses and competitive pressures. The 36.67% analyst buy rating and $18.07 consensus target suggest moderate upside potential, though regulatory concerns and market volatility remain key risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
